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Background 
 Summer 2015: New Delhi, India 
 All India Institute of Medical Sciences 
 Dept. of Gastroenterology and Human Nutrition 
Background (Cont.) 
 AIIMS is a federally funded hospital (and medical 
school) constantly kept on its feet due to the 
deluge of patients that desperately need care 
Research Project 
 How prevalent are certain blood borne infections 
(Hepatitis B (HBV), Hepatitis C (HCV), HIV) in 
patients who have certain Inflammatory Bowel 
Diseases (Ulcerative colitis, Crohn’s disease, and 
intestinal tuberculosis) compared to the 
prevalence of these infections in the general 
healthy population in India? 
Purpose of Research Project 
 Treatment for Inflammatory Bowel Disease (IBD) 
patients who have undetected/untreated Blood-Borne 
Infections (BBIs) is lethal 
 Treatment for IBD patients involves giving 
immunosuppressants (steroids, azathioprine, 
biologics)  
 HBV/HCV/HIV flares up as a result of 
immunosuppressive therapy 
 If prevalence of BBIs is higher in patients with IBD, 
must allocate necessary resources beforehand. If 
lower, must take away and place elsewhere for 
efficiency 
 Current information on prevalence is nebulous 
Primer on IBDs 
 Ulcerative Colitis (UC) 
 Chronic disease of the large intestine (colon) 
 Lining of colon becomes inflamed, develops ulcers 
 Abdominal discomfort, frequent colon emptying, higher chance 
of bloody stool 
 Crohn’s Disease (CD) 
 Same symptoms of UC, however unlike UC can affect any 
area of the GI tract  
 Can affect all layers of the bowel wall 
 Intestinal Tuberculosis (ITB) 
 Bacteria mycobacterium tuberculosis infects the GI tract 
 Diarrhea, low grade fever, cough, loss of weight 
 UC and CD are results of the immune system mistaking 
food, bacteria, and other materials in the tract for foreign 
invaders 
 
 
 
 
 
 
 
 
 
Disease 
Control 
Main 
Focuses 
Data-Collecting 
 Flipped through 3300+ medical files 
 If file had information on markers, was then noted 
on created research forms  
 Took 1.5 months 
 “Only” 1003 points 
Analyzing Data 
Analyzing Data (Cont.) 
 Basics: 
 1003 patients total 
 327 had Crohn’s disease 
 581 had Ulcerative Colitis 
 95 had ITB (Intestinal Tuberculosis) 
 CD (Crohn’s Disease) 
 M: 201 
 F: 126 
 Mean Age: 39.1 ± 13.9 yrs 
 UC (Ulcerative Colitis) 
 M: 340 
 F: 241 
 Mean Age: 36.9 ± 11.7 yrs 
 
 
Analyzing Data (Cont.) 
HBsAg antiHCV 
HIV 
HBV HCV 
“Fisher’s exact” is another way to 
say “p-value”. A p-value is a 
number that is calculated to 
determine if the data is significant 
or if it could just be due to chance. 
In this case, “significant data” is 
when the p-value is BELOW 0.05, 
and it would mean that there is 
either a distinctive high or low 
prevalence of BBIs in IBD patients 
that can’t be due to random 
chance (an actual trend). 
Analyzing Data (Cont.) 
 Prevalence of HBV, HCV, and HIV in the general Indian 
population is 3.7%, 1%, and 0.3% respectively (National AIDS 
Control Organization and National Center for Disease Control) 
 Questionable 
 In study, prevalence of HBV, HCV, and HIV in IBD patients (UC 
and CD combined) was 2.4% (20/829), 1.4% (11/791), and 0.1% 
(1/776) respectively 
 When compared to general pop., p-values are 0.05, 0.26, and 
0.31 respectively 
 In patients with UC, prevalence of HBV was 2.2% (12/541), HCV 
1.7% (9/518), and HIV 0.2%  
 When compared to general pop., P-values were 0.07, 0.09, and 
0.68 respectively 
 In CD patients, prevalence of HBV was 2.8% (8/288) and of HCV 
was 0.7% (2/273). No CD patients had HIV. 
  P-values were 0.41 and 0.65 respectively 
 In ITB patients, prevalence of HBV was 5.9% (4/67), HCV 1.8% 
(1/57), and HIV 1.2% (1/84). 
 
Analyzing Data (Cont.) 
 Prevalence of BBIs (Blood Borne Infections) in 
UC (Ulcerative Colitis) patients 
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HBV is more prevalent 
(or more widely 
detected) than HCV 
and HIV. This makes 
sense, as HBV kills a 
person the fastest. 
Analyzing Data (Cont.) 
 Prevalence of BBIs (Blood Borne Infections) in 
CD (Crohn’s Disease) patients 
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In CD patients, the 
trend is the same. 
HBV is more widely 
reported compared to 
HCV and HIV. 
Conclusion from Data 
 Prevalence of BBIs in patients with IBD is not 
statistically different from the general 
population in India 
 Routine screening for BBIs should continue on at 
similar rates to the current standard 
Limitations to the Study 
 Has a retrospective design 
 Hence would not be considered to not truly show 
the current state of matters 
 However, the database is continuously maintained, so if 
something new developed, it would have been updated 
 Not all patients had all three viral markers written 
in-file 
 Viral markers were tested for at first appointment, 
not later 
 Something could have developed later on, or 
patients who recently contracted an infection would 
still test negative (“false negative”) 
 
Related Studies 
 Similar studies have been conducted in China, 
France, Italy, and Spain 
 This study is the first to be done in India 
 China: Yao He et al showed no difference in 
prevalence compared to his patients and the 
general Southern Chinese population 
 Italy: Biacone et al saw a difference 
 France: Longo et al saw a difference 
 Spain: Loras et al did not see a difference 
 
 
Conclusion 
 Treatment for inflammatory bowel disease 
patients who have undetected/untreated blood-
borne infections is lethal 
 HBV, HCV, and HIV flare up as a result of treatment 
 Prevalence of infections in IBD patients was 
studied to see if resources could be used more 
efficiently 
 Study showed no significant prevalence of 
infections compared to the general population 
 Routine screening for BBIs should continue on at 
similar rates to the current standard 
 
 
 
